Table 3.
Summary of discontinuation/persistence studies with a latanoprost cohort and at least one comparator cohort
| Reference | Study type | Patients | Duration | Results | ||||
|---|---|---|---|---|---|---|---|---|
| Dasgupta et al103 | Retrospective cohort study | 1,330 | Relative risk for therapy discontinuation or change | Relative risk for therapy discontinuation (excluding change) | ||||
| Latanoprost | 1 | 1 | ||||||
| Beta-blockers | 1.24 | 1.63 | ||||||
| Carbonic anhydrase inhibitors | 2.22 | 2.37 | ||||||
| Shaya et al104 | Retrospective cohort study | 72,744 | 325 days | Relative risk for discontinuation (adjusted for sex and age) (CI) | ||||
| Latanoprost | 1 | |||||||
| Timolol | 1.34 [1.27–1.41] | |||||||
| Brimonidine | 1,54 [1.45–1.62] | |||||||
| Spooner et al105 | Retrospective observational cohort study | 1,006 | 18 months | Hazard ratio (95% CI) | ||||
| Latanoprost | 1 | |||||||
| Timolol | 1.73 (1.40–2.15) | |||||||
| Betaxolol | 1.63 (1.20–2.21) | |||||||
| Brimonidine | 1.70 (1.22–2.34) | |||||||
| Reardon et al106 | Retrospective cohort study | 7,527 | 180 days | Relative risk of discontinuation | Relative risk of discontinuation or change in therapy | |||
| Latanoprost | 1 (P<0.001) | 1 (P<0.001) | ||||||
| Bimatoprost | 1.38 (1.24–1.36) | 1.31 (1.19–1.44) | ||||||
| Travoprost | 1.36 (1.21–1.51) | 1.39 (1.17–1.42) | ||||||
| Brimonidine | 2.41 | 2.26 | ||||||
| Diestelhorst et al107 | Observational multicenter retrospective medical chart review | 260 | 2 years | Percentage of patients not switched | Percentage of patients switched more than twice | |||
| Latanoprost | 73.4% | 4.3% | ||||||
| Beta-blocker | 20.5% | 14.5% | ||||||
| Day et al108 | Retrospective multicenter parallel active controlled comparison | 1,182 | 1 year | Risk ratio to discontinue treatment | ||||
| Latanoprost | 1 | |||||||
| Bimatoprost | 1.15 (95% CI >1.01 to >1.16) | |||||||
| Beta blocker | 1.08 (95% CI >1.03 to >1.27) | |||||||
| Haverkamp et al109 | Switch to latanoprost | 1,068 | 36 months | Switch to latanoprost associated with: • Reduced intraocular pressure (P<0.0012) • Ocular allergy as the most common side effect • Patient preference for latanoprost |
||||
| Reardon et al110 | Retrospective cohort study | 28,741 | 1 year | Rate ratio for discontinuation of initial therapy | Patients having only one fill of index drug | |||
| Latanoprost | 1 | |||||||
| Timolol | 1.37 (95% CI 1.31–1.42) | 34 (P<0.001) | ||||||
| Brimonidine | 1.45 (95% CI 1.38–1.52) | 48 (P<0.001) | ||||||
| Betaxolol | 1.42 (95% CI 1.34–1.51) | 46 (P<0.001) | ||||||
| Dorzolamide | 1.41 (95% CI 1.30–1.53) | 52 (P<0.001) | ||||||
| Bimatoprost | 1.58 (95% CI 1.36–1.83) | 48 (P<0.001) | ||||||
| Travoprost | 1.72 (95% CI 1.50–1.97) | 50 (P<0.001) | ||||||
| Schwartz et al111 | Retrospective cohort study | 1,474 | 12 months | No discontinuation of therapy | No discontinuation or change in therapy | |||
| Latanoprost | 39% | 30% | ||||||
| Timolol | 25% | 18% | ||||||
| Wilensky et al112 | Retrospective population-based study | 2,424 | 12 months | Percentage of patients persistent for 12 months | Mean adherence | Number of days adherent | ||
| Latanoprost | 69.4% | 75.4% | 287 | |||||
| Travoprost | 70.6% | 77.1% | 281 | |||||
| Bimatoprost | 68.1% | 78.2% | 291.2 | |||||
| Bhosle et al113 | Retrospective observational cohort study | 268 | 1 year | Treatment adherence rate | Medication persistence | |||
| Latanoprost | 0.51±0.26 | Hazard ratio 0.9 | ||||||
| Other treatment | 0.40±0.25 | (95% CI 0.68–0.98) | ||||||
| Zimmerman et al114 | Prospective multicenter active historical-controlled trial | Pharmacy claims data for 6,271 patients | 2001–2004 | Continuous refill of prescription during 1 year | Patients persisting for 1 year or restarting medication | Patients switched to other medications | Overall discontinuation of treatment | |
| Latanoprost | 11% (P<0.0001) | 68% (P<0.0001) | 17% (P<0.0001) | 18% (P<0.0047) | ||||
| Bimatoprost | 9% | 61 | 21% | 21% | ||||
| Travoprost | 5% | 58% | 21% | 21% | ||||
| Arias et al115 | Retrospective observational cohort study | 191 | 24 months | No discontinuation of treatment | ||||
| Latanoprost | 81.6% (P<0.0001) | |||||||
| Bimatoprost | 22.9% | |||||||
| Travoprost | 65.4% | |||||||
| Timolol | 60.5% | |||||||
| Friström et al116 | Open-label multicenter time-on-therapy study | 326 | 36 months | Mean time to treatment failure | Patients remaining on therapy at 36 months | |||
| Latanoprost | 36 months (P<0.001) | 51% | ||||||
| Non-PG therapy | 12 months | 24% | ||||||
| Reardon et al117 | Retrospective cohort study | 7,873 | 358 days | Medication possession | Days covered | |||
| Latanoprost | 31% (P<0.001) | 141±89 (P<0.001) | ||||||
| Bimatoprost | 23% | 119±80 | ||||||
| Travoprost | 43% | 108±76 | ||||||
| Rahman et al118 | Retrospective analysis of medical records | 1,006 | 1997–2001 and 2002–2009 | Hazard ratio for time to initial treatment change; 1997–2001 (95% CI) | Hazard ratio for time to treatment change; 2002–2009 (95% CI) | |||
| Betaxolol versus latanoprost | 2.59 (2.02–3.32) | |||||||
| Brimonidine versus latanoprost | 2.55 (1.76–3.69) | |||||||
| Timolol versus latanoprost | 1.49 (1.05–2.11) | |||||||
| Bimatoprost versus latanoprost | 1.18 (0.71–1.97) | |||||||
| Travoprost versus latanoprost | 0.75 (0.51–1.12) | |||||||
Abbreviations: CI, confidence interval; PG, prostaglandin.